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Variable numbers of CD34+ cells can be harvested from the
blood of AML patients in CR after G-CSF supported mobiliz-
ation following consolidation chemotherapy. We hypothesized
that a decreased ability to mobilize stem cells reflects a chemo-
therapy-induced reduction in the number of normal and leu-
kemic stem cells. We therefore analyzed whether the mobilizing
capacity of these patients was of prognostic significance. 342
AML-patients in first CR received daily G-CSF from day 20 of
the consolidation course and underwent 1–6 aphereses to
obtain a minimum dose of 2 x 106 CD34+ cells/kg. Afterwards
they were randomized for autologous bone marrow (BM) or
blood SCT. As a surrogate marker for the mobilizing capacity,
the highest yield of CD34+ cells of a single apheresis was
adopted. Patients could be categorized into four groups: no
harvest (n = 76), low yield (1 x 106 CD34+/kg; n = 50), inter-
mediate yield (1–6.9 x 106 CD34+ cells/kg; n = 128) and high
yield (7 x 106 CD34+ cells/kg; n = 88). The median follow-up
was 3.4 years; 163 relapses and 16 deaths in CR were reported.
Autologous blood or BM SCT was performed in 36%, 64%, 81%
and 88%, respectively, of the patients assigned to the no har-
vest, low, intermediate and high CD34+ yield group. The 3-year
disease-free survival rate was 46.7%, 65.0%, 50.4% and 26.9%
(P = 0.0002) and the relapse incidence was 47.5%, 30.1%, 43.1%
and 71.9% (P  0.0001). Multivariate Cox’s proportional hazards
model showed that the CD34+ yield was the most important
independent prognostic variable (P = 0.005) after cytogenetics.
Patients with the highest mobilizing capacity have a poor prog-
nosis due to an increased relapse incidence.
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Introduction
Over the past decade, management of patients with acute
myeloid leukemia has gradually improved as the result of
intensiﬁcation of treatment and better supportive care. Auto-
logous bone marrow transplantation (ABMT) has been increas-
ingly used as a treatment modality for patients with AML
younger than 60 years of age. Several large randomized trials
have indicated the superior antileukemic activity of ABMT.1–5
Therefore, ABMT has become the treatment of ﬁrst choice in
many European centers for patients in complete remission
who lack a suitable donor for allogeneic transplantation.
Prolonged pancytopenia following transplantation has
emerged as a major drawback of ABMT. In an attempt to
accelerate hematopoietic reconstitution following transplan-
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tation, autologous cytokine mobilized peripheral blood stem
cells have been successfully used.6–10 However, despite its
widespread clinical usage, the efﬁcacy with respect to relapse
rate remains unproven. This question is now being addressed
by the EORTC and GIMEMA leukemia groups in a ran-
domized study (AML-10) comparing autologous blood stem
cell transplantation (ABSCT) and ABMT.11
In this study, it was attempted to harvest G-CSF
(lenograstim) mobilized blood stem cells in all patients
recovering from consolidation chemotherapy. Patients were
subsequently randomized to undergo an ABMT or ABSCT.
Since we encountered a highly variable yield of mobilized
CD34+ cells among patients, we hypothesized that a
decreased ability to mobilize stem cells may reﬂect a chemo-
therapy-induced reduction in the number of normal and leu-
kemic stem cells. For this reason, we analyzed whether the
mobilizing capacity for patients with AML in complete
remission was of prognostic signiﬁcance. Our results indicate
that patients mobilizing high numbers of CD34+ cells after
consolidation chemotherapy, irrespective of whether they
received a transplant or not, had an adverse prognosis and
exhibited a higher relapse rate. Therefore the capacity to har-
vest high numbers of CD34+ cells can be considered as an
independent poor prognostic factor.
Patients and methods
Study design
The AML 10 trial of the EORTC and GIMEMA Leukemia
Groups started in 1993 and included adult patients (60
years) with newly diagnosed AML. In the ﬁrst randomization
three different intercalating agents (daunorubicine, mitoxan-
trone and idarubicine) in combination with cytarabine and
etoposide were compared for induction and consolidation
treatment. In 1994, a second randomization was introduced
comparing ABMT and autologous blood stem cell transplan-
tation (ABSCT) in patients in complete remission who lacked
a HLA-identical family donor. The protocol has been
reviewed and approved by the relevant institutional ethics
committees, and all patients gave informed consent. They
received consolidation chemotherapy consisting of intermedi-
ate dose Ara-C (500 mg/m2, twice daily for 6 days) and 3 days
of the randomized intercalating agent.12 Mobilization and har-
vest of autologous blood stem cells was planned for all these
patients independent of the assignment of the second ran-
domization and was scheduled during the recovery phase of
the consolidation course. Lenograstim (150 g/m2) was given
Stem cells mobilizing capacity in AML: a strong prognostic factor
S Keating et al
61
by daily subcutaneous injections from day 20 of the consoli-
dation course until completion of the blood stem cell collec-
tions. Blood stem cell collections were performed on 1–5 con-
secutive days during the hematopoietic recovery phase, as
soon as the leukocyte counts exceeded 2 x 109/l or the CD34+
cells in the blood exceeded 2 x 107/l. According to the proto-
col, the total blood stem cell harvest should contain a target
dose of at least 2 x 106/kg body weight CD34+ cells. Those
patients who were randomized for transplantation with bone
marrow cells subsequently underwent a bone marrow
harvesting procedure under general anesthesia.
As a surrogate marker for the mobilizing capacity after con-
solidation treatment, we adopted the highest yield of a single
apheresis cycle. The total number of CD34+ cells harvested
could not be used for this purpose since this was inﬂuenced
by the predeﬁned target of 2 x 106 CD34+ cells/kg.
Patients
Three hundred and ninety-six patients were candidates for this
study. A total of 54 could not been included since six patients
had less than 5 days of lenograstim with insufﬁcient harvest,
35 patients started the lenograstim too late (after day 30 of
consolidation course), six stopped lenograstim before the start
of apheresis, one patient died at the end of the apheresis, and
in six patients the number of CD34+ cells was unknown.
Hence 342 patients were eligible for further analysis.
Criteria of evaluation
The CALGB criteria for response to treatment and relapse were
used.13 CR was deﬁned as morphological normal marrow with
less than 5% blasts, and normal peripheral blood and differen-
tial counts. Among patients who reached CR, relapse was
deﬁned as the presence of 10% blasts in the bone marrow,
or blasts in extramedullary sites. As cytogenetic classiﬁcation
the ISCN system has been applied.14. The patients with
unknown, not done or unsuccessful cytogenetics were
grouped together as ‘unknown’.
Statistical analysis
The disease-free survival (DFS) was calculated from the start
of lenograstim for mobilization of stem cells until the date of
ﬁrst relapse or of death in ﬁrst CR; patients alive and in ﬁrst
CR were censored at their last follow-up. The disease-free
interval (DFI) was calculated as the DFS, except that patients
who died in CR were censored at that moment. The duration
of survival was calculated from the date of start of lenograstim
until the date of death; patients still alive were censored at
their last follow-up.
Actuarial curves were calculated according to the Kaplan–
Meier technique. The standard errors (s.e.) of the estimates
were computed using the Greenwood formula. The estimates
of the incidence of relapse and of death in CR, and their corre-
sponding standard errors, were obtained using the cumulative
incidence method, where the risks of death in CR and of
relapse were considered as competing risks.15 The differences
between actuarial curves were tested for statistical signiﬁ-
cance using the two-tailed log-rank test, whereas for the
cumulative incidences the Gray test has been used.15 The
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Cox’s proportional hazards model has been used to obtain the
estimate and the 95% conﬁdence interval of the hazard ratio
(HR) of the instantaneous event rate in one group vs the one
in another group, as speciﬁed by a given variable, and the
Wald test has been used to determine the prognostic signiﬁ-
cance.15 The Cox model has also been used to determine the
independent prognostic factors among those that appeared
important in univariate analyses (P  0.1). All analyses were
based on the intent-to-treat principle. The relationships
between the four groups and patient characteristics have been
tested using the generalized Wilcoxon test.15
The cut-off date was 8 April 2002. SAS 8.1 statistical
software has been used.
Results
Mobilization characteristics
The median day to start lenograstim was 20 days (range 10–
29) from the start of the consolidation course. The median
duration of lenograstim administration was 8 days (range 1–
37). In 76 patients the number of CD34+ cells in the blood
remained below the threshold for starting an apheresis in spite
of a median duration of lenograstim administration of 13 days
(range 5–37). In the other 266 patients the ﬁrst apheresis
started after a median of 2 days (range 0–9 days) of lenogras-
tim administration, and the median number of aphereses per-
formed was 2 (range 1–6). The median of the total number of
CD34+ cells in all apheresis products harvested in a particular
patient (total graft) was 6 x 106/kg (range 0.1–246.4 x 106/kg).
Based on the highest harvest of CD34+ cells obtained during
a single apheresis 50 patients were considered to have a low
CD34+ yield (1 x 106/kg), 128 patients an intermediate
CD34+ yield (1–6.9 x 106/kg) and 88 patients a high CD34+
yield (7 x 106/kg). The correlation between the highest
CD34+ yield, considering the cut-points at 1 and 7 x 106/kg,
and the total yield of CD34+ harvested, taking the cut-point
at 2 and 10 x 106/kg, was extremely high (data not shown).
The number of days from the day of starting of lenograstim to
the ﬁrst harvest was 9, 6 and 4 days, respectively for the three
groups, low, intermediate and high yield.
Relationship with initial patient characteristics and
initial treatment schedule
Patient characteristics of the four groups are presented in
Table 1. The 50 patients in the low CD34+ yield group were
younger (median age 38 vs 46 years for all others) and had a
higher initial WBC count (median of 32.9 vs 14 x 109/l for all
others). The distribution regarding FAB subtype, CD34
expression on the leukemic blasts at diagnosis, the CR rate
after the ﬁrst induction course, and the percentage of patients
not randomized were similar in the four groups. The cyto-
genetic prognostic subgroups were unevenly distributed
between the four CD34+ yield groups, ie the no harvest group
contained more patients with favorable and less patients with
unfavorable cytogenetics, whereas the high CD34+ yield
group contained less good risk patients (Table 1).
The distribution of the three initially randomized arms for
either daunorubicin, mitoxantrone or idarubicine varied to a
great extent per CD34+ yield group (Table 2). The high CD34+
yield group contained more patients randomized to the dau-
norubicin arm. The median duration of administration of leno-
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Table 1 Patient characteristics according to CD34+ yield group
No harvest Low yield Intermediate yield High yield P-value
n = 76 n = 50 n = 128 n = 88
Age (years) (median) 50 38 43.5 45 0.007
WBC (x109/l) (median) 12.1 32.9 13.1 15.7 0.06
Leukemic blasts 46 (60.5%) 42 (84.0%) 62 (44.9%) 45 (48.2%)
CD34+ assessed
30% CD34+ 25 (54.3%) 20 (47.6%) 36 (58.1%) 19 (42.2%) 0.39
30% CD34+ 21 (44.7%) 22 (52.4%) 26 (41.9%) 26 (57.8%)
FAB type
Unknown 3 (3.9%) 0 (0.0%) 2 (1.6%) 0 (0.0%)
M0 5 (6.6%) 0 (0.0%) 2 (1.6%) 2 (2.3%)
M1 12 (15.8%) 10 (20.0%) 15 (11.7%) 17 (19.3%)
M2 28 (36.8%) 17 (34.0%) 42 (32.8%) 26 (29.5%) 0.35a
M4 12 (15.8%) 10 (20.0%) 38 (29.7%) 20 (22.7%)
M5 13 (17.1%) 10 (20.0%) 25 (19.5%) 20 (22.7%)
M6 3 (3.9%) 3 (6.0%) 3 (2.3%) 3 (3.4%)
M7 0 (0.0%) 0 (0.0%) 1 (0.8%) 0 (0.0%)
Randomization
Not randomized 26 (34.2%) 18 (36.0%) 44 (34.4%) 28 (31.8%)
ABMT vs ABSCT 50 (65.8%) 32 (64.0%) 84 (65.6%) 60 (68.2%) 0.96
Courses to CR
1 72 (94.7%) 48 (96.0%) 119 (93.0%) 85 (96.6%)
2 4 (5.3%) 2 (4.0%) 9 (7.0%) 3 (3.4%) 0.67
Cytogenetics
Unknown 22 (28.9%) 10 (20.0%) 40 (31.3%) 27 (30.7%)
Successful 54 (71.1%) 40 (80.0%) 88 (68.7%) 61 (69.3%)
Good riskb 17 (31.5%) 12 (30.0%) 28 (31.8%) 10 (16.4%)
NN or −Y only 25 (46.3%) 15 (37.5%) 33 (37.5%) 22 (36.1%) 0.025
Bad riskc 12 (22.2%) 13 (32.5%) 27 (30.7%) 29 (47.5%)
Data in parentheses refer to percentages. Percentages in italic are calculated for those with a successful examination.
aFAB M2 or M4 vs all other FAB subtypes.
bPresence of t(8;21) or inv(16).
cPresence of −5, −7, 5q−, 7q−, 11q23, +8, t(9;22), 12p−, complex or other abnormalities.
ABMT, autologous bone marrow transplantation; ABSCT, autologous blood stem cell transplantation.
Table 2 Induction/consolidation treatment according to CD34+ yield group
No harvest Low yield Intermediate yield High yield P value
n = 76 n = 50 n = 128 n = 88
Randomized arm
DNR 13 (17.1%) 8 (16.0%) 56 (43.8%) 51 (58.0%)
MTZ 37 (48.7%) 28 (56.0%) 24 (18.8%) 22 (25.0%) 0.0001
IDA 26 (34.2%) 14 (28.0%) 48 (37.5%) 15 (17.0%)
DNR, daunorubicin; MTZ, mitoxantrone; IDA, idarubicin.
grastim was 5, 10 and 10 days for patients receiving daunoru-
bicin, mitoxantrone and idarubicin, respectively. An average
of 1.71, 1.68, 1.88 aphereses was performed in each treat-
ment group, respectively. More than 7 x 106/kg CD34+ cells
were harvested in a single apheresis in 51 (40%), 22 (20%)
and 15 (15%) patients, respectively, in the three treatment
groups (P  0.001).
Relationship between chemotherapy toxicity and
CD34+ yield (Table 3)
Hematological toxicity after the consolidation course differed
considerably: the higher the CD34+ yield, the shorter the dur-
ation of neutropenia and thrombocytopenia (P  0.0001). The
rates of grade 3–4 infections (21%, 20%, 16%, 12%) and
especially the duration of i.v. antibiotic administration
(P = 0.001) were inversely correlated with the CD34+ yield
(median of 17, 14, 11 and 13 days, respectively). The inci-
dence and severity of other organ toxicities, such as oral and
gastro-intestinal mucositis and liver toxicity were similar in the
four groups.
Relationship between CD34+ yield and transplantation
rate
From the 76 patients in the no-harvest group, 31 (41%) sub-
sequently had a successful harvest of either bone marrow
(n = 23), blood stem cells (n = 6) or combined (n = 2). Twenty-
seven (35.5%) underwent a stem cell transplantation (23
ABMT, 4 ABSCT). In the remaining three CD34+ yield groups,
sufﬁcient numbers of CD34+ cells from peripheral blood or
BM were harvested in the large majority of the patients to
undergo an autologous stem cell transplantation (74.0%,
94.4%, and 100% in the low, intermediate and high CD34+
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No harvest Low yield Intermediate yield High yield P value
n = 76 n = 50 n = 128 n = 88
Recovery
Days PLT 20 (median) 33 28 23 19 0.0001
Days PLT 100 (median) 63 52 35 25 0.0001
Days PMN 0.5 (median) 26 25 22 21 0.0001
Days PMN 1.5 (median) 30 27 24 23 0.0001
Organ toxicity
Mucositis 27 (35.5%) 22 (44.0%) 52 (40.6%) 30 (34.1%) 0.75
Diarrhea 24 (31.6%) 15 (30.0%) 40 (31.3%) 30 (34.1%) 0.85
Liver toxicity 16 (21.1%) 11 (22.0%) 29 (22.7%) 14 (15.9%) 0.62
PLT, platelet cell count (x109/l); PMN, polymorphonuclear cell count (x 109/l).
yield groups, respectively). Autologous PSC or BM transplan-
tation rates in ﬁrst CR were 64.0%, 81.3% and 87.5%,
respectively. In the high CD34+ yield, 11 (12.5%) patients
have not been auto-transplanted: one patient had an alloSCT
(protocol violation), nine relapsed (day 26–142) and one
remained in CCR (censored at day 81).
Effects of the CD34+ yield on outcome
The median follow-up was 41 months (range 1–82) and the
overall DFS rate at 3 years was 45.8%. Patients with a low
CD34+ yield had a higher DFS rate at 3 years, 65.0% (s.e.
6.9%), than those with no harvest, an intermediate or a high
CD34+ yield: 46.7% (s.e. 6.2%), 50.4% (s.e. 4.6%) and 26.9%
(s.e. 5.0%), respectively (Figure 1 and Table 4). The instan-
taneous event (relapse or death) rate in these last three groups
was 1.56, 1.55 and 2.72, respectively, higher than in the ﬁrst
group (P = 0.0002). The cumulative incidence of relapse at 3
years was lower in the group with the low CD34+ yield
(30.9%, s.e. 6.7%) compared to those with no harvest (47.5%,
s.e. 6.2%), an intermediate (43.1%, s.e. 4.6%) and high
CD34+ yield (71.9%, s.e. 5.2%) (P = 0.00001, Figure 2). The
instantaneous risk of relapse was 1.58, 1.50 and 3.01 greater
in these three groups, respectively, as compared with the
group with the low CD34+ yield. The cumulative incidence
of death in CR at 3 years was slightly lower in the group with
high CD34+ yield than in the others: 1.1% vs 4.1% to 6.4%.
The overall survival rate at 3 years from start of lenograstim
was the lowest (42.9%, s.e. 5.7%) in the high CD34+ yield
group and the highest (64.3%, s.e. 7.0%) in the low CD34+
yield group (overall P = 0.07). Using a value equal to zero
for the no harvest group, the relationship between the highest
CD34+ yield harvested on a single day and the DFS remained
Table 4 Estimated rates or incidences at 3 years according to CD34+ yield group
Endpoint No harvest Low yield Intermediate yield High yield P valuea
Disease-free survival rateb 46.7 (±6.2) 65.0 (±6.9) 50.4 (±4.6) 26.9 (±5.0) 0.0002 (0.0001)
Relapse incidencec 47.5 (±6.2) 30.9 (±6.7) 43.1 (±4.6) 71.9 (±5.2) 0.0001 (0.0001)
Death in CR incidencec 5.9 (±2.9) 4.1 (±2.9) 6.5 (±2.2) 1.1 (±1.1) 0.23 (0.11)
Survival rateb 55.3 (±6.0) 64.3 (±7.0 59.9 (±4.7) 42.9 (±5.6) 0.07 (0.014)
Data are expressed as percentage (±s.e.).
aP value given by the logrank test or Gray test; between brackets, P value given by the logrank test for linear trend or Gray test comparing
the outcome of the three ordered CD34+ groups: low, intermediate and high yield.
bEstimate using the Kaplan–Meier method.
cEstimate of the cumulative incidence using the competing risk method.
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Figure 1 Disease-free survival from start of lenograstim according
to CD34+ yield group. N, number of patients; O, observed number of
events (relapse or death in ﬁrst CR). P value given by the logrank test.
important by using the median (2.1 x 106/kg) as a cut-point
(P = 0.03), or considering it as a continuous variable
(P = 0.002) or the log of the continuous variable (P = 0.001)
in a Cox model. The total of CD34+ yield also showed a strong
relationship with the DFS, when one considers it is as a cate-
gorized variable, with cut-points at 2 and 10 x 106/kg
(P = 0.0007), or as a continuous variable (P = 0.004).
Restricting the analysis to 266 patients who have been har-
vested, the highest CD34+ yield appeared to be highly predic-
tive for the DFS, time to relapse and even for duration of sur-
vival (Table 4). Similar results have been obtained by
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Figure 2 Cumulative incidence of relapse from start of lenograstim
according to CD34+ yield group. N, number of patients; O, observed
number of relapses. P value given by the Gray test.
considering the CD34+ yield as a continuous variable
(P = 0.003) or the log of the continuous variable (P = 0.001).
Multivariate analyses for disease-free survival (DFS)
and disease-free interval (DFI)
Prognostic factor analyses for the DFS revealed that patients
in the cytogenetic good risk group had a better outcome than
those with normal karyotype or −Y only (HR, 0.38;
P = 0.0005). The following factors were associated with a poor
outcome: cytogenetic bad risk group (HR, 1.74; P = 0.004),
FAB subtype different from M2 and M4 (HR, 1.64; P = 0.001),
CR reached after the second cycle of induction (HR, 1.76;
P = 0.06), patients not randomized (HR, 1.33; P = 0.07), pres-
ence of diarrhea during consolidation (HR, 1.45; P = 0.02). A
trend towards a worse prognosis was observed for those
patients with a shorter duration of pancytopenia after the con-
solidation course, ie neutrophils 1.5 x 109/l (22 vs 23–27
vs 28 days: P = 0.04) or platelet count 100 x 109/l (28
vs 28 days: P = 0.11). Age (P = 0.42), WBC (P = 0.22), the
type of intercalating agent used in the induction and consoli-
dation treatment (P = 0.35) had no prognostic value. Patients
with unknown cytogenetic analysis (n = 99) had a prognosis
very similar (HR, 0.94; P = 0.76) to those with normal NN kar-
yotype or −Y. The 3-year DFS rates for cytogenetic good, inter-
mediate (NN or −Y) and bad risk groups were 74.1%, 41.6%
and 24.9%, respectively, whereas for the group with an
unknown cytogenetics it was 49.2%.
Multivariate Cox’s proportional hazards model indicated
that cytogenetic risk group (low vs intermediate vs bad vs
unknown) was the most important prognostic factor
(P  0.0001). The Cox model stratiﬁed by cytogenetic risk
group showed that the CD34+ yield group was the most
important prognostic variable (P = 0.005) after the cytogenetic
risk group. The only additional variable which might have
been included was FAB type (HR, 1.30), but it was only mar-
ginally signiﬁcant (P = 0.095). The estimated hazard ratios
(95% conﬁdence intervals) of the no harvest, intermediate and
high CD34+ yield groups were 1.67 (0.94, 2.97), 1.59 (0.93,
2.73) and 2.46 (1.43, 4.23), respectively taking the low CD34+
yield group as reference, and stratifying by cytogenetics. Table
Table 5 Results of the Cox model regarding the disease-free sur-
vival where the two signiﬁcant factors have been retained
(cytogenetics and CD34+ yield group)
Variable Hazard ratioa (95% CI) P valueb
Cytogenetics
Good risk 0.38 (0.22, 0.69) 0.0006
Intermediate 1
Bad risk 1.62 (1.11, 2.36) 0.01
Unknown 0.89 (0.61, 1.32) 0.57
CD34 group
No harvest 1.70 (0.96, 3.02) 0.07
Low yield 1
Intermediate yield 1.60 (0.93, 2.74) 0.09
High yield 2.49 (1.45, 4.27) 0.001
CI, confidence interval.
aA value 1 indicates that the outcome is worse in that category
as compared with the baseline.
bP value given by the Wald test.
5 shows the joint prognostic importance of cytogenetics and
CD34+ yield group using a proportional hazards Cox model.
For the DFI analysis stratiﬁed by cytogenetic group, the esti-
mated hazard ratios for the three CD34+ risk groups were 1.71
(0.93, 3.15), 1.55 (0.87, 2.76) and 2.77 (1.57, 4.90), respect-
ively (P = 0.0006), and the cumulative incidences stratiﬁed for
cytogenetics were different as well (P = 0.0003).
Another parameterization of the CD34+ yield (continuous
variable or its logarithmic transformation, categorical variable
by using other cut-points) did not affect the conclusions of
these analyses. Interestingly, a signiﬁcant interaction
(P = 0.03) between the highest CD34+ yield considered as a
continuous variable and the cytogenetic risk group has been
detected: the prognostic importance of the highest CD34+
yield regarding the DFS was quite low in bad-risk cytogenetic
group (see Figure 3). The same lack of prognostic importance
has been noted for the FAB subtype. On the contrary, in the
remaining group of patients (n = 261) without bad cytogenetic
features, univariate analyses showed that the CD34+ yield was
of highly prognostic importance (P = 0.0005), cytogenetic
group (P = 0.0009) and FAB (P = 0.004). The Cox model strati-
ﬁed by cytogenetic group (low, intermediate or unknown)
Figure 3 Bad risk cytogenetic subgroup: disease-free survival from
start of lenograstim according to CD34+ yield group. N, number of
patients; O, observed number of events (relapse or death in ﬁrst CR).
P value given by the logrank test.
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Variable Hazard ratioa (95% CI) P valueb
Cytogenetics
Good risk 0.44 (0.25, 0.78) 0.0045
Intermediate 1
Unknown 0.87 (0.58, 1.30) 0.49
CD34 group
No harvest 1.69 (0.78, 3.63) 0.18
Low yield 1
Intermediate yield 2.21 (1.07, 4.56) 0.03
High yield 3.52 (1.69, 7.31) 0.0007
FAB
M2 or M4 1
Other subtypes 1.41 (0.96, 2.08) 0.08
Results of the Cox model regarding the disease-free survival where
the three factors (cytogenetics, CD34+ yield group and FAB) have
been considered.
CI, confidence interval.
aA value 1 indicates that the outcome is worse in that category
as compared with the baseline.
bP value given by the Wald test.
showed that the hazard ratios of the no harvest, intermediate
and high CD34+ yield groups were 1.83 (0.86, 3.91), 2.09
(1.02, 4.28) and 3.53 (1.70, 7.33), respectively, taking the low
CD34+ yield group as reference (P = 0.001). The joint prognos-
tic importance of cytogenetics, CD34 yield and FAB subtype
(marginally signiﬁcant) are shown in Table 6. Figure 4 shows
the prognostic importance of the CD34+ yield group in
patients with low, intermediate or unknown cytogenetics.
Discussion
The present study was undertaken to test the prognostic sig-
niﬁcance of the capacity to mobilize hematopoietic stem cells
after consolidation chemotherapy and lenograstim in patients
with AML. This was based on the assumption that the mobiliz-
ing capacity after consolidation chemotherapy is a reﬂection
of the size of the stem cell pool and that the latter may be
inversely related with the sensitivity to chemotherapy. We
Figure 4 Low, intermediate or unknown cytogenetic risk sub-
group: disease-free survival from start of lenograstim according to
CD34+ yield group. N, number of patients; O, observed number of
events (relapse or death in ﬁrst CR). P value given by the logrank test.
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found a relationship between the mobilizing capacity after
intensive chemotherapy and lenograstim administration and
the subsequent risk of relapse. Patients with the highest yield
of CD34+ cells (7 x 106/kg) in a single apheresis had the
highest relapse incidence and the shortest disease-free sur-
vival, whereas patients with the lowest number of CD34+ cells
(1 x 106/kg) in the harvest showed the longest disease-free
survival. The strong prognostic importance of the CD34+ yield
remained valid in a multivariate analysis, after adjusting for
possible confounding factors, such as cytogenetics16,17 and
FAB subtype. Thus, although a signiﬁcant correlation existed
between the CD34+ yield and cytogenetics, the CD34+ yield
represents an important independent risk factor for time to
relapse and DFS. If one distinguishes a very bad risk cytog-
enetic group containing those with −5/5q−, −7/7q−, 11q23,
+8, t(9;22), 12p− or complex abnormalities, and/or consider-
ing other FAB grouping (M2 or M4E vs other subgroups) the
results were extremely similar (data not shown). Different stat-
istical analyses which have been performed regarding the
highest CD34+ or the total CD34+ yield, considering them as
a categorical or a continuous variables, all pointed in the same
direction: the higher the CD34+ cell count, the worse the prog-
nosis. This appeared to be particularly true in patients without
bad risk cytogenetic features.
To explain this phenomenon we considered several possi-
bilities. One hypothesis is that increasing numbers of leu-
kemic cells present in the graft result in a higher relapse risk
after transplantation.18 Although we cannot exclude this possi-
bility it is unlikely for several reasons. Firstly, the proportion
of CD34+ blast cells at diagnosis was not different between
patients in the high CD34+ yield and the low CD34+ yield
group. Secondly, dynamics of relapse in the CD34+ high yield
group was similar to the other groups within the ﬁrst 5 months
after the start of lenograstim, and only thereafter, especially
within 6–12 months, there was a divergence of the DFS and
relapse curves. These data suggest that the high relapse risk
for patients in the high CD34+ yield group was unlikely to be
due, exclusively, to contamination with leukemic cells. ‘Late’
divergences of the DFS curves, between 1 and 2.5 years, have
been observed in the previous AML-8A study, where patients
randomized to received a second cycle of consolidation had
a continuously higher risk of relapse than those randomized
to an ASCT group.4 Therefore an insufﬁcient in vivo purging
is a more likely explanation for the worse prognosis observed
in the high yield group, although one may not exclude com-
pletely the ﬁrst explanation.
The group with the highest CD34+ yield had the shortest
duration of neutropenia and thrombocytopenia after the con-
solidation course, whereas patients with the lowest CD34+
yield exhibited the longest duration of pancytopenia. Thus,
the low yield may reﬂect a more effective in vivo purging,
resulting in less normal and leukemic stem cells. Conversely,
the highest CD34+ yield, which coincides with the shortest
pancytopenia and the highest relapse risk, could be due to a
relatively low sensitivity for chemotherapy of the leukemic, as
well as the normal progenitor cells. Thus, the high CD34+
counts in the harvest is associated with a high occult leukemia
burden in the patient. A relationship with other organ tox-
icities could not be detected. These ﬁndings may be in line
with a yet undetermined polymorphism of the hematopoietic
progenitor cells for intracellular drug metabolism, resulting in
reduced sensitivity for chemotherapy. The conditioning before
transplantation did not result in a high eradication of leukemic
cells, since the group of patients with the highest CD34 yield
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had the highest and fastest relapse rate despite the highest per-
centage of performed autologous transplantation (88%).
The average relapse rate and disease-free survival and the
longest lasting pancytopenia of the patients in whom the mob-
ilization failed completely may be explained by the possibility
that this group consists of a mixture of different kinds of
patients. Some may be highly chemotherapy sensitive; the
preceding consolidation course results in an extended bone
marrow aplasia with a prolonged neutropenia and thrombocy-
topenia and a very low relapse risk. Some other patients may
have persisting leukemia in the bone marrow which, for
unknown reasons, prevents the normal bone marrow repopu-
lation, blood cell recovery and CD34+ mobilization. Attempts
to discriminate the prognosis of the no harvest patients
according to the duration of neutropenia or thrombocytopenia
failed so far (data not shown). The trend towards a poorer
prognosis of the patients with no harvest as compared with
those with a low CD34+ yield may also be explained by a
difference in their subsequent transplantation rate (36% vs
64%). These patients tended to be older (median, 50 years);
however age per se did not appear to be of prognostic
importance in this study.
We conclude that mobilization of high numbers of CD34+
cells after intensive consolidation treatment is an independent
poor prognostic factor. We hypothesize that this may be
explained by a genetic polymorphism that determines the sen-
sitivity for chemotherapy. This observation may have impli-
cations for additional treatment before and/or after transplan-
tation for this subgroup with a high risk of relapse, especially
in those with an intermediate cytogenetic risk group. Other
treatment modalities, such as immunotherapy or allogeneic
stem cell transplantation, should also be considered.
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